300毫克与100毫克依替奈单抗治疗偏头痛的比较：随机对照研究的荟萃分析
Comparison of eptinezumab 300 mg with 100 mg for the treatment of migraine: a meta-analysis of randomized controlled studies.
作者信息
Wang Jing, Li Xingchuan, Yang Zhiguo, Baowang Yang, Zhang Ni
机构信息
Department of Children's Intensive Care Medicine, The Second Hospital of Lanzhou University, Lanzhou, Gansu Province 730000.
Department of Gastroenterology, The Second Hospital of Lanzhou University, Lanzhou, Gansu.
出版信息
Afr Health Sci. 2024 Sep;24(3):393-400. doi: 10.4314/ahs.v24i3.43.
INTRODUCTION
The efficacy and safety of eptinezumab 300 mg versus 100 mg for migraine remains debatable. We conduct this meta-analysis to compare eptinezumab 300 mg with 100 mg on the treatment of migraine.
METHODS
We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through April 2021 for randomized controlled trials (RCTs) assessing the effect of eptinezumab 300 mg versus 100 mg on treatment efficacy and safety in migraine patients. This meta-analysis was performed using the random-effect model.
RESULTS
Four RCTs were included in the meta-analysis. Overall, compared with eptinezumab 100 mg in migraine patients, eptinezumab 300 mg was associated with substantially improved 75% responder rate (OR=1.34; 95% CI=1.06 to 1.69; P=0.01), but demonstrated similar monthly migraine days (MD=-0.09; 95% CI=-0.20 to 0.01; P=0.08), 100% responder rate (OR=1.38; 95% CI=0.94 to 2.02; P=0.10), 50% responder rate (OR=1.20; 95% CI=0.97 to 1.48; P=0.10), migraine 1 day after dosing (OR=0.92; 95% CI=0.72 to 1.18; P=0.52), adverse events (OR=1.13; 95% CI=0.77 to 1.65; P=0.53), nasopharyngitis (OR=1.26; 95% CI=0.74 to 2.14; P=0.40), upper respiratory tract infection (OR=1.25; 95% CI=0.83 to 1.88; P=0.29), sinusitis (OR=1.78; 95% CI=0.95 to 3.33; P=0.07) or nausea (OR=1.26; 95% CI=0.68 to 2.32; P=0.46).
CONCLUSIONS
Eptinezumab 300 mg may have better efficacy for migraine patients than eptinezumab 100 mg.
引言
300毫克与100毫克依替奈珠单抗治疗偏头痛的疗效和安全性仍存在争议。我们进行这项荟萃分析以比较300毫克依替奈珠单抗与100毫克依替奈珠单抗治疗偏头痛的效果。
方法
我们检索了截至2021年4月的PubMed、EMbase、Web of science、EBSCO和Cochrane图书馆数据库，以查找评估300毫克与100毫克依替奈珠单抗对偏头痛患者治疗疗效和安全性影响的随机对照试验（RCT）。本荟萃分析采用随机效应模型进行。
结果
荟萃分析纳入了四项RCT。总体而言，与偏头痛患者使用100毫克依替奈珠单抗相比，300毫克依替奈珠单抗使75%缓解率显著提高（OR=1.34；95%CI=1.06至1.69；P=0.01），但每月偏头痛天数相似（MD=-0.09；95%CI=-0.20至0.01；P=0.08），100%缓解率（OR=1.38；95%CI=0.94至2.02；P=0.10），50%缓解率（OR=1.20；95%CI=0.97至1.48；P=0.10），给药后1天偏头痛（OR=0.92；95%CI=0.72至1.18；P=0.52），不良事件（OR=1.13；95%CI=0.77至1.65；P=0.53），鼻咽炎（OR=1.26；95%CI=0.74至2.14；P=0.40），上呼吸道感染（OR=1.25；95%CI=0.83至1.88；P=0.29），鼻窦炎（OR=1.78；95%CI=0.95至3.33；P=0.07）或恶心（OR=1.26；95%CI=0.68至2.32；P=0.46）。
结论
对于偏头痛患者，300毫克依替奈珠单抗可能比100毫克依替奈珠单抗疗效更好。
Zotero 插件